Second Generation Antipsychotics and Risk of Diabetes Type II - Comparison between Olanzapine and Risperidone

Filaković, Pavo; Koić, Oliver; Laufer, Davor; Radanović-Grgurić, Ljiljana; Degmečić, Dunja; Požgain, Ivan

Pregled bibliografske jedinice broj: 719252

Second Generation Antipsychotics and Risk of Diabetes Type II - Comparison between Olanzapine and Risperidone

Filaković, Pavo; Koić, Oliver; Laufer, Davor; Radanović-Grgurić, Ljiljana; Degmečić, Dunja; Požgain, Ivan

Second Generation Antipsychotics and Risk of Diabetes Type II - Comparison between Olanzapine and Risperidone // Collegium antropologicum, 31 (2007), 4; 1105-1109 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 719252 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Second Generation Antipsychotics and Risk of Diabetes Type II - Comparison between Olanzapine and Risperidone
(Diabetes Type II - Comparison between Olanzapine and Risperidone)

Autori
Filaković, Pavo ; Koić, Oliver ; Laufer, Davor ; Radanović-Grgurić, Ljiljana ; Degmečić, Dunja ; Požgain, Ivan

Izvornik
Collegium antropologicum (0350-6134) 31 (2007), 4; 1105-1109

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
schizophrenia ; secong generation antipsychotics ; glucose metabolism

Sažetak
Differences in the glucose metabolism were examined in this study between patient treated with olansapine and risperidone in comparison with healthy volunteers. Authors conclude that insuline resistence is the main mechanism for development of diabetes type II in the schizophrenic patients treated with antipsychotics.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
219-1081870-2070 - Mehanizam nastanka metaboličkog sindroma induciran antipsihoticima (Filaković, Pavo, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Osijek

Profili:

Ivan Požgain (autor)